Since 1989, we have led the ascertainment,evaluation, and genetic analysesof the NIMH GeneticsInitiative Alzheimer's disease (AD) sample. This set of AD families, which currently includes 457 families, is the argest uniformly ascertained and evaluated sample assembled for the study of AD genetics. Over the first ive years of this R37, we have continued to carry out genetic analysesand follow-up studies of our a high- resolution whole genome genetic linkage screen for novel AD candidate genes. We have focused on linkage peaks identified on chromosomes 9 and 10, and identified late-onsetAD candidate genes in both ofthese inkage peaks: insulin degrading enzyme (IDE;10q) and ubiquilin 1 (UBQLN1;9q). In addition tofunctionally characterizing these genes for potential pathogenic effects in AD, we have built a highly efficient gene discovery pipeline, customized for large-scale generation, confirmation, storage and analysis of SNP genotype information. Our NIMH family-based association database of positional candidate gene contains over 500,000 genotypes for more than 300 SNPs in over 150 genestested in the full NIMH sample. Furthermore, we have recently obtained nearly one billion genotypes for the NIMH sample from a high- density, whole genome association screen using the Affymetrix 500K SNPchip, currently under analysis. By early October, we will also have obtained the results of a screen of the Affymetrix20,000 coding region SNPs (cSNPs) for the entire NIMH AD family sample. This screen should identify SNPs with a higher probability of potentially pathologenic effects.These combined data sets now provide anunprecedented array of AD candidate genes collectively accounting for as much as 95% of the genetic van'ability of AD. In the second half of this R37, we will carry out confirmatory and follow-up studies of these AD candidate genes. First, SNPs exhibiting family-basedassociation with AD will be confirmed by manual genotyping. Second, they will be confirmed in additional AD family-based samples. Third, tagging SNPs for all inkage disequilibrium blocks in confirmed candidate genes will be tested in the NIMH and confirmatory samples. Fourth, bioinformatic analyses and resequencing will be performed to identify potentially pathogenic mutations and gene variants. The strongest candidate genes will then be validated in a wide array of functional analyses to assess the potential pathogenicity of AD-associatedgene variants.

National Institute of Health (NIH)
National Institute of Mental Health (NIMH)
Method to Extend Research in Time (MERIT) Award (R37)
Project #
Application #
Study Section
Special Emphasis Panel (NSS)
Program Officer
Addington, Anjene M
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Massachusetts General Hospital
United States
Zip Code
Hooli, Basavaraj V; Parrado, Antonio R; Mullin, Kristina et al. (2014) The rare TREM2 R47H variant exerts only a modest effect on Alzheimer disease risk. Neurology 83:1353-8
Choi, Se Hoon; Kim, Young Hye; Hebisch, Matthias et al. (2014) A three-dimensional human neural cell culture model of Alzheimer's disease. Nature 515:274-8
Won, Sungho; Lu, Qing; Bertram, Lars et al. (2012) On the meta-analysis of genome-wide association studies: a robust and efficient approach to combine population and family-based studies. Hum Hered 73:35-46
Hooli, B V; Mohapatra, G; Mattheisen, M et al. (2012) Role of common and rare APP DNA sequence variants in Alzheimer disease. Neurology 78:1250-7
Bertram, Lars; Tanzi, Rudolph E (2010) Alzheimer disease: New light on an old CLU. Nat Rev Neurol 6:11-3
O'Brien, J L; O'Keefe, K M; LaViolette, P S et al. (2010) Longitudinal fMRI in elderly reveals loss of hippocampal activation with clinical decline. Neurology 74:1969-76
Giedraitis, Vilmantas; Glaser, Anna; Sarajarvi, Timo et al. (2010) CALHM1 P86L polymorphism does not alter amyloid-beta or tau in cerebrospinal fluid. Neurosci Lett 469:265-7
Zhang, Can; Browne, Andrew; Child, Daniel et al. (2010) Loss of function of ATXN1 increases amyloid beta-protein levels by potentiating beta-secretase processing of beta-amyloid precursor protein. J Biol Chem 285:8515-26
Schjeide, Brit-Maren M; McQueen, Matthew B; Mullin, Kristina et al. (2009) Assessment of Alzheimer's disease case-control associations using family-based methods. Neurogenetics 10:19-25
Schjeide, Brit-Maren M; Hooli, Basavaraj; Parkinson, Michele et al. (2009) GAB2 as an Alzheimer disease susceptibility gene: follow-up of genomewide association results. Arch Neurol 66:250-4

Showing the most recent 10 out of 32 publications